• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

F-star Therapeutics, Inc. - Common Stock (NQ:FSTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about F-star Therapeutics, Inc. - Common Stock

News headline image
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
March 08, 2023
From invoX Pharma
Via Business Wire
News headline image
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
March 07, 2023
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer 
From F-star Therapeutics, Inc.
Via GlobeNewswire
News headline image
invoX Pharma and F-star Therapeutics issue Joint Statement
January 26, 2023
From F-star Therapeutics, Inc.
Via GlobeNewswire
News headline image
F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress
December 06, 2022
FS222 demonstrated early antitumor activity with one complete response and six disease stabilizations in patients with advanced solid tumors 
From F-star Therapeutics, Inc.
Via GlobeNewswire
News headline image
F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research
November 07, 2022
From F-star Therapeutics, Inc.
Via GlobeNewswire
News headline image
F-STAR THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX
July 15, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
FSTX STOCK ALERT: Halper Sadeh LLP Is Investigating Whether the Sale of F-star Therapeutics, Inc. Is Fair to Shareholders
July 14, 2022
From Halper Sadeh LLP
Via Business Wire
News headline image
F-STAR THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX
June 23, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
FSTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of F-star Therapeutics, Inc. Is Fair to Shareholders
June 23, 2022
From Halper Sadeh LLP
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap